English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

The role of genetics for biomarker development in neurodegeneration

MPS-Authors
/persons/resource/persons50098

Bertram,  L.
Neuropsychiatric Genetics (Lars Bertram), Dept. of Vertebrate Genomics (Head: Hans Lehrach), Max Planck Institute for Molecular Genetics, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Bertram, L., & Hampel, H. (2011). The role of genetics for biomarker development in neurodegeneration. Progress in Neurobiology, 95(4), 501-4. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/22005514 http://pdn.sciencedirect.com/science?_ob=MiamiImageURL&_cid=271063&_user=28761&_pii=S030100821100178X&_check=y&_origin=article&_zone=toolbar&_coverDate=31-Dec-2011&view=c&originContentFamily=serial&wchp=dGLbVlt-zSkzV&md5=669cdcb634187e64aaf4a4b67f7b7540/1-s2.0-S030100821100178X-main.pdf http://pdn.sciencedirect.com/science?_ob=MiamiImageURL&_cid=271063&_user=28761&_pii=S030100821100178X&_check=y&_origin=article&_zone=toolbar&_coverDate=31-Dec-2011&view=c&originContentFamily=serial&wchp=dGLbVlk-zSkzS&md5=669cdcb634187e64aaf4a4b67f7b7540/1-s2.0-S030100821100178X-main.pdf.


Cite as: https://hdl.handle.net/11858/00-001M-0000-0010-7900-6
Abstract
Research on biomarkers and genetics shares a number of objectives, including the identification of novel disease mechanisms, optimization of therapeutic studies, and improvement of diagnosis and prognosis. The latter is of particular relevance in neurodegenerative diseases where the underlying molecular processes often go on for decades until the first clinical symptoms appear. In this commentary we review the potential contribution that insight gained from genetic research may have on biomarker development in neurodegeneration. We argue that future progress will largely depend on a widespread application of novel high-throughput technologies now becoming available in both fields.